# reload+after+2024-01-21 18:43:06.911776
address1§12830 El Camino Real
address2§Suite 400
city§San Diego
state§CA
zip§92130
country§United States
phone§858 558 2871
fax§858 212 0513
website§https://acadia.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
fullTimeEmployees§580
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Stephen R. Davis J.D.', 'age': 62, 'title': 'President, CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1458270, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark C. Schneyer', 'age': 49, 'title': 'Executive VP & CFO', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 701028, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brendan P. Teehan', 'age': 54, 'title': 'Executive VP, COO & Head of Commercial', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 724310, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Austin D. Kim', 'age': 59, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 722149, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James K. Kihara', 'age': 42, 'title': 'VP, Chief Accounting Officer & Corporate Controller', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Albert S. Kildani', 'title': 'Senior Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Julie  Fisher', 'title': 'Senior Vice President of Marketing & Commercial Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Holly  Valdiviez', 'title': 'Senior VP & Head of Sales', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rob  Ackles', 'title': 'Senior VP & Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bob  Mischler', 'title': 'Senior Vice President of New Product Planning & Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§4
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.593
priceToSalesTrailing12Months§7.8805027
currency§USD
dateShortInterest§1702598400
forwardEps§1.0
pegRatio§0.25
exchange§NMS
quoteType§EQUITY
shortName§ACADIA Pharmaceuticals Inc.
longName§ACADIA Pharmaceuticals Inc.
firstTradeDateEpochUtc§1085664600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e64b7e43-7c59-3150-9bbf-f928af706124
gmtOffSetMilliseconds§-18000000
targetHighPrice§42.0
targetLowPrice§14.0
targetMeanPrice§33.61
targetMedianPrice§35.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§18
quickRatio§2.101
grossMargins§0.3879
ebitdaMargins§-0.23736
trailingPegRatio§None
